Treatment of Unresectable Advanced Non Small Cell Lung Cancer (NSCLC)
|
|
- Rosa Bradford
- 7 years ago
- Views:
Transcription
1 Treatment of Unresectable Advanced Non Small Cell Lung Cancer (NSCLC)
2 ASCO 2007: Treatment of Unresectable Advanced Non Small Cell Lung Cancer (NSCLC) Bevacizumab improves progression-free survival in advanced NSCLC Erlotinib has clinical activity in first-line treatment of unselected patients with advanced NSCLC, particularly in never smokers Improved survival and response rates with cetuximab plus gemcitabine/platinum vs. gemcitabine/platinum alone as first-line treatment for advanced NSCLC Bevacizumab plus chemotherapy fails to improve survival compared with chemotherapy alone in older patients with NSCLC
3 Bevacizumab improves progression-free survival in advanced NSCLC Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Manegold C, et al. ASCO 2007: Abstract LBA7514.
4 Background Bevacizumab is an antiangiogenic monoclonal antibody that targets the vascular endothelial growth factor ECOG (E4599) trial: pivotal phase III study of bevacizumab (15 mg/kg) added to a combination of paclitaxel and carboplatin as first-line therapy for advanced NSCLC demonstrated survival advantage of bevacizumab combination compared with chemotherapy alone (12.5 mos vs.10.2 mos; p <.0075) 1 established a new standard for first-line therapy for eligible patients with advanced non-squamous NSCLC by showing that a triplet regimen containing a biologic agent can improve survival in this setting 1. Sandler A, et al. N Engl J Med ECOG = Eastern Cooperative Oncology Group NSCLC = non small cell lung cancer Q3W = every 3 weeks
5 Background (continued) U.S. FDA subsequently approved bevacizumab (15 mg/kg Q3W) in combination with platinum-based therapy (carboplatin and paclitaxel) for initial systemic treatment of patients with unresectable, locally advanced, recurrent or metastatic, non-squamous NSCLC In Canada, bevacizumab currently only indicated for first-line treatment of advanced colorectal cancer Contraindications to bevacizumab use include squamous cell histology, brain metastases, history of hemoptysis, or need for anticoagulation therapy 1 AEs associated with combination therapy in E4599 included neutropenia, hemorrhage, hypertension and proteinuria Important to integrate results of the pivotal clinical trial into practice and appropriately expand use of antiangiogenics such as bevacizumab into the larger patient population 1. Sandler A, et al. N Engl J Med AE = adverse effect FDA = Food and Drug Adminstration (U.S.) NSCLC = non small cell lung cancer Q3W = every 3 weeks
6 Background (continued) Avastin in Lung (AVAiL) trial: European and Canadian trial of similar design to the U.S. E4599 trial Randomized, double-blind, multicentre phase III trial Designed to evaluate 2 doses of bevacizumab (7.5 or 15 mg/kg Q3W) in combination with a platinum doublet (gemcitabine and cisplatin) chemotherapy in patients with previously untreated, advanced NSCLC with histology other than predominant squamous cell 1 PFS data (primary endpoint of this study) presented at ASCO Manegold C, et al. ASCO 2007: Abstract LBA7514. ECOG = Eastern Cooperative Oncology Group NSCLC = non small cell lung cancer PFS = performance-free status Q3W = every 3 weeks
7 Study design Total of 1,043 patients with treatment-naïve advanced NSCLC (Table 1) enrolled and randomly assigned in this three-arm trial: Cisplatin 80 mg/m 2 day 1 + gemcitabine 1,250 mg/m 2 days 1 and 8 + placebo, day 1 Cisplatin 80 mg/m 2 day 1 + gemcitabine 1,250 mg/m 2 days 1 and 8 + bevacizumab 7.5 mg/kg, day 1 Cisplatin 80 mg/m 2 day 1 + gemcitabine 1,250 mg/m 2 days 1 and 8 + bevacizumab 15 mg/kg, day 1 Manegold C, et al. ASCO 2007: Abstract LBA7514. Bv = bevacizumab CG = cisplatin/gemcitabine NSCLC = non small cell lung cancer PD = progressive disease
8 Baseline characteristics Manegold C, et al. ASCO 2007: Abstract LBA7514. CG = cisplatin/gemcitabine
9 Study design (continued) Treatment administered Q3W, for a maximum of 6 cycles Bevacizumab continued until progression or unacceptable toxicity Response assessed every 3 cycles of treatment (rather than every two cycles as in E4599) Inclusion criteria included non-squamous histology and PS of 0 to 1 Exclusion criteria included Hemoptysis grade 2 or higher Evidence of invasion of major blood vessels Brain metastases Uncontrolled hypertension Primary objective: demonstrate superiority in PFS of both bevacizumab-containing treatment arms vs. control Secondary outcomes: OS, RR, duration of response, and toxicity OS = overall survival PFS = progression-free survival PS = performance status Q3W = every 3 weeks Manegold C, et al. ASCO 2007: Abstract LBA7514. RR = response rate
10 Key findings HR for progression on bevacizumab (7.5 mg/kg) vs. pooled placebo was 0.75 (95% CI: ; p = ) (Figure 1 below) (Figure 2 for 15 mg/kg bevacizumab) Manegold C, et al. ASCO 2007: Abstract LBA7514. Bv = bevacizumab CG = cisplatin/gemcitabine CI = confidence interval HR = hazard ratio PFS = progression-free survivalrr = response rate
11 Manegold C, et al. ASCO 2007: Abstract LBA7514. Bv = bevacizumab CG = cisplatin/gemcitabine CI = confidence interval HR = hazard ratio PFS = progression-free survival
12 Key findings (continued) Tumour RR was 34% in the 7.5 mg/kg arm (p = ), 30% in the 15 mg/kg arm, and 20% in the control arm (p < ) (Table 2) Bevacizumab therapy was associated with a more durable tumour response: 6.1 mos vs. 4.7 mos (Table 2) Manegold C, et al. ASCO 2007: Abstract LBA7514. CG = cisplatin/gemcitabine CI = confidence interval PFS = progression-free survival RR = response rate
13 Key findings (continued) Approximately 7% of patients in the trial had started second-line treatment prior to documented progressive disease After a pre-planned analysis to correct for these patients, HRs for PFS were 0.68 (95% CI, ; p = ) and 0.74 (95% CI, ; p = ) for the bevacizumab 7.5 mg/kg and 15 mg/kg arms, respectively Manegold C, et al. ASCO 2007: Abstract LBA7514. CI = confidence interval HR = hazard ration PFS = progression-free survival RR = response rate
14 Safety Neutropenia, thrombocytopenia, and anemia were the most common AEs in all arms (Table 3 below) Manegold C, et al. ASCO 2007: Abstract LBA7514. AE = adverse event CG = cisplatin/gemcitabine
15 Safety (continued) Addition of bevacizumab did not significantly increase rate of AEs, SAEs, or treatment-related deaths when compared to control arm There were 4% treatment-related deaths in the control arm, 4% in the low-dose bevacizumab arm, and 5% in the 15 mg/kg arm Rate of severe (grade 3) pulmonary hemorrhage comparable between groups 2 patients vs. 5 patients vs. 3 patients (control, 7.5, 15); of the 10 patients, only 4 had central lesions Nine per cent of total trial patients had therapeutic anticoagulation, but none suffered any severe pulmonary hemorrhage events Six per cent of patients in low-dose bevacizumab arm and 9% of patients in high-dose arm had grade 3 or higher hypertensions vs. 2% of control patients Manegold C, et al. ASCO 2007: Abstract LBA7514. AE = adverse event SAE = serious adverse event
16 Key conclusions This is the second randomized phase III trial to show benefit from bevacizumab therapy in advanced NSCLC for PFS and RR AVAiL confirms findings of E4599 in terms of improved RR and TTP with bevacizumab HRs of 0.75 and 0.82 observed slightly higher than the HR of 0.66 in E4599 trial. Dr. Thomas Lynch postulated that subtle differences in patient populations, assessment every 3 cycles in the AVAiL as opposed to 2 cycles in E4599, and use of a cisplatin-containing regimen may account for some of the difference Secondary endpoint data for survival expected in 2008 Bevacizumab in combination with cisplatin and gemcitabine well tolerated; no new safety signals observed, and incidence of severe hemoptysis or pulmonary hemorrhage was low at 1.5% Manegold C, et al. ASCO 2007: Abstract LBA7514. HR = hazard ratio NSCLC = non small cell lung cancer PFS = progression-free survival RR = response rate TTP = time to progression
17 Canadian perspective by Dr. Hirsh Encouraging to see that bevacizumab plays a role in first-line treatment of NSCLC We now have 2 trials that show advantage of addition of bevacizumab to standard chemotherapy and as maintenance therapy in a selected group of patients; this therapy should become the new standard for treatment in non-squamous NSCLC Important to note that this study used a European standard chemotherapy regimen rather than the carboplatin-paclitaxel regimen used with bevacizumab in the U.S. However, clinical benefit of bevacizumab is independent of type of chemotherapy it is combined with Study not powered to test OS, nor designed to compare 2 doses of bevacizumab to each other but rather to non-bevacizumab arm Manegold C, et al. ASCO 2007: Abstract LBA7514. NSCLC = non small cell lung cancer OS = overall survival
18 Canadian perspective (continued) Difficult to distinguish which dose was best, as CIs in both bevacizumab arms crossed. No clear difference in efficacy between the 7.5 mg/kg and 15 mg/kg dose, and perhaps even a slight (statistically non-significant) improvement in tumour RR and PFS in the 7.5 mg/kg arm Demonstration of benefit of 7.5 mg/kg dose of bevacizumab is important for Canada, as drug will presumably be more cost-effective at this dose If we exclude all patients not eligible to enter the two bevacizumab phase III first-line trials of NSCLC with stage III B/IV, we will be able to treat only 25 30% of patients Manegold C, et al. ASCO 2007: Abstract LBA7514. CI = confidence interval NSCLC = non small cell lung cancer PFS = progression-free survival RR = response rate
19 Erlotinib has clinical activity in firstline treatment of unselected patients with advanced NSCLC, particularly in never smokers Erlotinib for first-line treatment in unselected patients (p) with advanced or metastatic non small cell lung cancer (NSCLC) Jimenez U, et al. ASCO 2007: Abstract 7639.
20 Background Goals of therapy for advanced NSCLC are to improve survival and to provide palliation of symptoms Recommended first-line treatment of patients with good PS is platinum-based chemotherapy, often in combination with a thirdgeneration cytotoxic compound such as gemcitabine, paclitaxel, or docetaxel 1 Degree of toxicity associated with platinum-based regimens, such as nephrotoxicity, neurotoxicity, and myelosuppression, may restrict use in older patients or those with a poor PS 1. Ramalingam S, Sandler AB. Oncologist NSCLC = non small cell lung cancer PS = performance status
21 Background (continued) Erlotinib, an oral EGFR TKI, approved for patients with advanced or metastatic NSCLC who have failed at least one prior chemotherapy regimen Erlotinib was first EGFR inhibitor to show survival benefit in previously treated NSCLC in a randomized, placebo-controlled setting 1 Single-agent therapy with erlotinib has been explored as option to combination chemotherapy in first-line treatment of unselected group of patients with advanced NSCLC 2 1. Shepherd FA, et al. N Engl J Med Jimenez U, et al. ASCO 2007: Abstract EGFR = epidermal growth factor receptor NSCLC = non small cell lung cancer TKI = tyrosine kinase inhibitor
22 Study design Spanish TargeT trial (1,796 patients enrolled) was an open-label, non-randomized phase II trial evaluating the efficacy and safety of erlotinib in patients with either locally advanced or metastatic NSCLC Primary endpoint: TTP in the ITT population with erlotinib administered as first, second, and third or successive lines of treatment Secondary endpoints included clinical benefit (CR, PR, and SD), overall survival, and safety Patients received erlotinib 150 mg/day until disease progression or withdrawal Jimenez U, et al. ASCO 2007: Abstract CR = complete response ITT = intent to treat NSCLC = non small cell lung cancer PR = partial resonse SD = stable disease TTP = time to progression
23 Study design (continued) Tumour response measured by CT scan, performed every 6 weeks, and evaluated according to RECIST criteria Safety of erlotinib was determined by NCI CTCAE v3.0 Present study is subanalysis of a subset of these unselected, chemotherapy-naïve patients (n = 461). Of these patients, 259 had measurable disease and were evaluated for response (Table 1) Jimenez U, et al. ASCO 2007: Abstract CTCAE = common terminology criteria for adverse events ECOG PS = Eastern Cooperative Oncology Group performance status NCI = National Cancer Institute NSCLC = non small cell lung cancer RECIST = response evaluation criteria in solid tumours
24 Key findings Median TTP was 6.6 months among 259 evaluable patients (95% CI: ) Never smokers receiving erlotinib had approximately 6 month longer TTP (Figure 1) and improved overall survival (Figure 2) than current or ever smokers Jimenez U, et al. ASCO 2007: Abstract CI = confidence interval HR = hazard ratio TTP = time to progression PFS = progression-free survival
25 Jimenez U, et al. ASCO 2007: Abstract CI = confidence interval HR = hazard ratio
26 Key findings (continued) Overall response rate was 32% (Table 2) Females, never smokers, and patients with adenocarcinoma histology had better response rates Safety Mild-to-moderate rash was the most common AE (62.3% of patients); 3 cases of grade 4 rash (0.78%) Diarrhea was next most common AE at 39.5%; of reported diarrhea cases 0.5% were grade 4 Jimenez U, et al. ASCO 2007: Abstract AE = adverse event
27 Jimenez U, et al. ASCO 2007: Abstract CI = confidence interval CR = complete response PR = partial response SD = stable disease
28 Key conclusions Study confirms clinical activity of erlotinib in unselected NSCLC patients who had not received prior chemotherapy for advanced disease: median TTP of almost 7 months in all patients and 11 months in never smokers First-line erlotinib therapy able to achieve disease control in 71% of patients, independent of disease histology Smoking history and gender predictive factors for tumour response In multivariate analysis, absence of smoking history and good PS associated with a longer survival Jimenez U, et al. ASCO 2007: Abstract NSCLC = non small cell lung cancer PS = performance status TTP = time to progression
29 Canadian perspective by Dr. Hirsh Improved response in never smokers fits with previously published BR.21 study, which showed erlotinib beneficial in both smokers and never smokers, but more effective in patients who had never smoked 1 Most clinical benefit with TKI of EGFR is seen in never smokers, women, and adenocarcinomas; this trial confirms it 1. Clark GM, et al. Clin Lung Cancer EGFR = epidermal growth factor receptor TKI = tyrosine kinase inhibitor
30 Improved survival and response rates with cetuximab plus gemcitabine/platinum vs. gemcitabine/platinum alone as first-line treatment for advanced NSCLC Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC) Butts CA, et al. ASCO 2007: Abstract 7539.
31 1. Govindan R. Clin Cancer Res Robert F, et al. J Clin Oncol Rosell R, et al. J Clin Oncol Gatzemeier U, et al. Proc Am Soc Clin Oncol Kelly K, et al. Proc Am Soc Clin Oncol Butts CA, et al. ASCO 2007: Abstract NSCLC = non small cell lung cancer Background Cetuximab is monoclonal antibody that blocks ligand binding to extracellular domain of the epidermal growth factor receptor 1 Cetuximab has been studied in phase I and II trials in combination with chemotherapy as first-line therapy for metastatic NSCLC, with resulting response rates of 23% to 53% 2-5 Addition of cetuximab to chemotherapy appears to be well tolerated and with acceptable toxicity Question remains whether cetuximab adds any clinical benefit over chemotherapy alone in unselected or selected patient populations Early, and encouraging, safety and efficacy results presented at ASCO 2007 of current open-label, randomized phase II study designed to compare gemcitabine and a platinum (cisplatin or carboplatin) alone with the same combination with cetuximab in patients with previously untreated, advanced NSCLC 6
32 Study design Trial was small noncomparative, open-label, randomized phase II trial of gemcitabine and platinum chemotherapy with or without the addition of cetuximab (Figure 1) Eligible patients were: chemotherapy-naïve Stage IIIB or IV NSCLC and an ECOG PS of 0 or 1 (Table 1) No crossover allowed between treatment groups Primary outcome: overall response rate Secondary outcomes: progression-free survival, overall survival, and safety Butts CA, et al. ASCO 2007: Abstract ECOG = Eastern Cooperative Oncology Group NSCLC = non small cell lung cancer PS = performance status
33 Figure 1: Treatment schema Butts CA, et al. ASCO 2007: Abstract AUC = area under curve
34 Patient demographics Butts CA, et al. ASCO 2007: Abstract BAC = bronchoalveolar carcinoma
35 Key findings Cetuximab added to chemotherapy suggests possibility of improvements in overall response rate, progression-free survival, and overall survival (Table 2) Butts CA, et al. ASCO 2007: Abstract CI = confidence interval
36 Safety Addition of cetuximab to chemotherapy regimens appears to be relatively well tolerated, with fatigue, nausea, anorexia, and acneiform rash as distinguishing adverse events in the cetuximab arm (Table 3) Butts CA, et al. ASCO 2007: Abstract 7539.
37 Key conclusions Response rates improved when cetuximab was added to gemcitabine and platinum-based chemotherapy regimens, compared with gemcitabine and platinum-based chemotherapy alone, as first-line therapy in advanced NSCLC Early results suggest that addition of cetuximab may also prolong progression-free and overall survival Cetuximab plus chemotherapy regimen well tolerated Two other randomized phase III trials have completed recruitment and should report next year Butts CA, et al. ASCO 2007: Abstract NSCLC = non small cell lung cancer
38 Canadian perspective by Dr. Hirsh This randomized phase II trial was too small to make any firm conclusions; at this point, the survival data look promising Benefit of cetuximab of a similar magnitude to that of bevacizumab in the ECOG 4599 trial Main difference between studies was that this cetuximab trial enrolled a group of patients using a wider eligibility criteria; data may be more widely applicable to the general population It will be interesting to see if results of two other trials compare well to this trial We certainly need a larger, phase III trial results to see impact on our practice Butts CA, et al. ASCO 2007: Abstract 7539.
39 Bevacizumab plus chemotherapy fails to improve survival compared with chemotherapy alone in older patients with NSCLC Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study Ramalingam SS, et al. ASCO 2007: Abstract 7535.
40 Background Older patients ( 65 years of age) account for approximately 50% of all lung cancer patients, yet few randomized clinical trials enroll significant numbers of older patients, making it difficult to assess efficacy and toxicity of new agents in this subgroup 1 Older patients often have comorbidities or physiologic characteristics, such as altered drug metabolism and reduced hepatic and renal functions, that make their treatment more challenging 1 Present study 2 is retrospective analysis of the safety and efficacy profiles in the subgroup of older patients (aged 70 years or older) enrolled in published E4599 trial 3 (see the earlier discussion of the AVAiL trial 4 on slides 3 to 17) 1. Gridelli C, et al. Ann Oncol Ramalingam SS, et al. ASCO 2007: Abstract Sandler AB, et al. N Engl J Med Erratum in: N Engl J Med Manegold C, et al. ASCO 2007: Abstract LBA7514.
41 Study design Eligibility criteria for the initial trial included non-squamous NSCLC and ECOG PS 0 or 1 For subgroup analysis, elderly patients defined as age 70 or older at the time of study entry (Table 1) Those younger than 70 years of age comprised the non-elderly group Ramalingam SS, et al. ASCO 2007: Abstract ECOG = Eastern Cooperative Oncology Group NSCLC = non small cell lung cancer PS = performance status
42 Baseline characteristics Ramalingam SS, et al. ASCO 2007: Abstract ECOG = Eastern Cooperative Oncology Group NOS = not otherwise specified PC = paclitaxel/carboplatin PCB = paclitaxel/carboplatin/bevacizumab PS = performance status
43 Key findings Number of eligible cases from E4599 was 850 (PC: n = 433, PCB: n = 417) 70 years: n = 224 (26%) 80 years: (1.6%) Proportion of elderly patients in ECOG 4599 was highest recorded among ECOG phase III trials (26%) Median age of elderly group was 74 years, while median age of non-elderly group was 63 years Efficacy data comparable between treatment regimens in both elderly and non-elderly cohorts (Table 2) Ramalingam SS, et al. ASCO 2007: Abstract ECOG = Eastern Cooperative Oncology Group PC = paclitaxel/carboplatin PCB = paclitaxel/carboplatin/bevacizumab
44 Efficacy data for elderly vs. non-elderly group Ramalingam SS, et al. ASCO 2007: Abstract CR = complete response PC = paclitaxel/carboplatin PCB = paclitaxel/carboplatin/bevacizumab PFS = progressive-free disease PR = partial response SD = stable disease
45 Safety Grade 3 or 4 toxicity more common in elderly patients (Table 3) More treatment-related deaths in elderly group (7 deaths vs. 2 deaths in non-elderly, p = 0.10) Ramalingam SS, et al. ASCO 2007: Abstract PC = paclitaxel/carboplatin PCB = paclitaxel/carboplatin/bevacizumab
46 Key conclusions Analysis shows similar outcome of triplet therapy for elderly patients compared with younger counterparts in terms of RR and OS Improvement in survival and PFS seen in non-elderly cohort with addition of bevacizumab to standard chemotherapy; no significant improvement noted in elderly Addition of bevacizumab associated with higher degree of toxicity when compared to paclitaxel-carboplatin alone Note that this is retrospective study percentage of elderly patients enrolled in E4599 study 1 with bevacizumab did not exceed 26% of actual study population Safety and efficacy of bevacizumab-chemotherapy combinations in elderly patients with NSCLC requires more scrutiny 1. Sandler AB, et al. N Engl J Med Erratum in: N Engl J Med NSCLC = non small cell lung cancer OS = overall survival PFS = progession-free survival RR = response rate
47 Canadian perspective by Dr. Hirsh Comparatively large number of older patients (n = 222) who had a PS of 0 or 1 enrolled in this trial Clinical trials generally designed to test efficacy of a treatment intended for a population consisting of a majority of younger patients; only selected proportion of elderly patients will be considered for enrollment, as in this study Results of such trials may not necessarily extend to general non-selected elderly population (which would include patients with a PS of 2) and should be treated with caution Caution is required as to whether to give patients older than 70 years of age bevacizumab in addition to chemotherapy, because of increased toxicity seen in retrospective subanalysis of elderly patients in this trial and lack of survival benefit with bevacizumab in this group Ramalingam SS, et al. ASCO 2007: Abstract PS = performance status
48 Canadian perspective (continued) Three drugs may not be better than two in case of elderly patients with advanced NSCLC Standard third-generation, single-agent chemotherapies such as vinorelbine and gemcitabine already have proven efficacy with manageable toxicity in this population Functional status can be measured as activities of daily living (ADL) and instrumental ADL (IADL); IADL may prove to be significant prognostic value for survival of elderly patients with advanced NSCLC treated with chemotherapy Use of these scores in clinical practice might improve prediction for patients who will likely benefit from agents like bevacizumab; this needs to be tested prospectively Ramalingam SS, et al. ASCO 2007: Abstract ADL = activities of daily living IADL = instrumental activities of daily living NSCLC = non small cell lung cancer
Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationTreatment Paradigm in NSCLC Treatment
Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationTargeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee
More informationSYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE
Which patients with stage IV NSCLC should be treated with chemotherapy? NSCLC with nonsquamous cell carcinoma, negative or unknown EGFR-sensitizing mutation and ALK gene rearrangement status, and PS 0-1
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationElderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment?
4 The Open Lung Cancer Journal, 2011, 4, 4-9 Open Access Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment? Antonio Rossi * Division of Medical Oncology, S.G. Moscati Hospital,
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationShifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer
J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,
More informationAnti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationBNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationCome è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
More informationTargeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
More information( targeted therapy ) ( oncogenesis ) ( epidermal. growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( epidermal growth
2008 19 8-13 growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( targeted therapy ) ( oncogenesis ) ( epidermal factor receptor monoclonal antibody EGFR-moAb ) growth factor monoclonal antibody
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationStrength of Study End Point(s): Progression-free survival
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationREPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer
More informationThird-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationChemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
More informationThorakale Onkologie. ASCO 2013 Aktuelle Studien TZ Berlin Buch 12.6.2013
Triple negativ Thorakale Onkologie ASCO 2013 Aktuelle Studien TZ Berlin Buch 12.6.2013 Driver Oncogene Mutations in non sq-nsclc Genome Res. 2012 November; 22(11): 2109 2119 8021: Detection of EGFR-activating
More informationTreatment of Stage IV Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest
More informationIs there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer?
Original Article Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Rajappa S, Gundeti S, Uppalapati S, Jiwatani S, Abhyankar A, Pal C,
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationSEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years
Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):
More informationMAINTENANCE CHEMOTHERAPY
1 MAINTENANCE CHEMOTHERAPY FOR ADVANCED NSCLC Dr.M.V.Nagarjuna OBJECTIVES OF THIS SEMINAR 1. Definitions 2. Switch maintenance 3. Continuation Maintenance 4. Immunotherapy as maintenance 5. Conclusions
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationClinical Study Report
An Open, Multi-Center, Phase II Clinical Trial to Evaluate Efficacy and Safety of Taxol (), UFT, and Leucovorin in Patients with Advanced Gastric Cancer Clinical Study Report 4F, No. 156, Jiankang Rd.,
More informationNew Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationConsiderations and Challenges in Treating Elderly Patients with Lung Cancer, by Dr. Rogerio Lilenbaum
Considerations and Challenges in Treating Elderly Patients with Lung Cancer, by Dr. Rogerio Lilenbaum Dr. West: Hello, and welcome. My name is Dr. Jack West, and I m a medical oncologist in Seattle Washington
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationThird-line therapy in advanced non-small cell lung cancer
JBUON 3; (): 99-97 ISSN: 7-65, online ISSN: -693 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Third-line therapy in advanced non-small cell lung cancer Zhen Ying Geng,, Shun Chang
More informationHow valuable is a cancer therapy? It depends on who you ask.
How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr
More informationNON-SMALL CELL LUNG CANCER STAGE IV
NON-SMALL CELL LUNG CANCER STAGE IV Effective Date: November, 2013 The recommendations contained in this guideline are a consensus of the Alberta Provincial Thoracic Tumour Team synthesis of currently
More informationPreliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors
Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto
More informationSAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
More informationAdditional 50 patients enrolled in KEYNOTE-001 with analyses planned using Merck s proprietary PD-L1 assay at one percent and 50 percent cut points
News Release Media Contacts: Annick Robinson Dominique Quirion Merck NATIONAL Annick.robinson@merck.com dquirion@national.ca 514 428-2890 514 843-2302 Investor Contacts: Justin Holko: (+1 908-423-5088
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationCancer patients waiting for potentially live-saving treatments in UK
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationLONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012
Background LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 The incidence of pancreatic cancer in the UK is 9.4/100,000. It is
More informationHighlights in NSCLC From the 15th World Conference on Lung Cancer
January 214 Volume 12, Issue 1, Supplement 1 A SPECIAL MEETING REVIEW EDITION Highlights in CLC From the 15th World Conference on Lung Cancer A Review of Selected Presentations From the 15th World Conference
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationThe NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
More informationP! P! P! 2nd Mess! P! P! P! P! P! Signaling Cascade. Signaling Cascade. Signaling Cascade. Signaling Cascade. Signaling Cascade
Vaccine-Associated! Sarcoma! Hemangiosarcoma! Mast Cell Tumor! Osteosarcoma! 10 11! Survival! Survival Migration/Invasion! Survival Migration/Invasion Angiogenesis! Survival Migration/Invasion Angiogenesis
More informationSonneveld, P; de Ridder, M; van der Lelie, H; et al. J Clin Oncology, 13 (10) : 2530-2539 Oct 1995
Comparison of Doxorubicin and Mitoxantrone in the Treatment of Elderly Patients with Advanced Diffuse Non-Hodgkin's Lymphoma Using CHOP Versus CNOP Chemotherapy. Sonneveld, P; de Ridder, M; van der Lelie,
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
More informationKRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationNon-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
More informationActive centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationNOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Philippe RUSZNIEWSKI
NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Réunion APRAMEN, Paris, 2 février 2013 Philippe RUSZNIEWSKI Pôle des Maladies de
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationClinical Spotlight in Breast Cancer
2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared
More information1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:
1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationSystemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Introduction The purpose of this guideline update is to revise the 2011
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationPfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014
Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will
More informationChemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status
Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status Tracey L. Evans, MD Abstract In spite of advances in molecular profiling
More information